One drug that is commonly tapped for off-label use is immune globulin, a drug derived from human plasma that helps fight infection. The drug is FDA approved for six conditions, some of which have no other available therapies and can be life-threatening.
While prescribing a drug off-label is legal and often leads to new and effective uses for drugs, a 2017 study published by the American Academy of Allergy, Asthma and Immunology found intravenous immune globulin is often prescribed for off-label conditions where it is ineffective and could actually increase risks to patients.
There was a 66 percent increase in distribution of intravenous immune globulin between 2012 and 2018 across North America and Europe because of an increase in off-label use, according to the report.
Hospitals and clinics nationwide have reported a shortage of the drug, and have had to ration or suspend treatment for many patients. Some facilities have stopped giving the drug to patients with diseases deemed to be non-life threatening and are saving the treatment for those who need it to stay alive.
Read the full report here.
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.